{"Symbol": "ARGX", "AssetType": "Common Stock", "Name": "argenx NV ADR", "Description": "argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.", "CIK": "1697862", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "LIFE SCIENCES", "Industry": "BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)", "Address": "INDUSTRIEPARK ZQIJNAARDE 7, BUILDING C B-9052, ZWIJNAARDE, BE", "OfficialSite": "https://argenx.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-03-31", "MarketCapitalization": "33977573000", "EBITDA": "190978000", "PERatio": "33.89", "PEGRatio": "0", "BookValue": "90.49", "DividendPerShare": "None", "DividendYield": "None", "EPS": "16.38", "RevenuePerShareTTM": "1.754", "ProfitMargin": "0.403", "OperatingMarginTTM": "0.175", "ReturnOnAssetsTTM": "-0.0021", "ReturnOnEquityTTM": "0.174", "RevenueTTM": "2643062000", "GrossProfitTTM": "1310622000", "DilutedEPSTTM": "16.38", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0.957", "AnalystTargetPrice": "772.46", "AnalystRatingStrongBuy": "7", "AnalystRatingBuy": "15", "AnalystRatingHold": "1", "AnalystRatingSell": "0", "AnalystRatingStrongSell": "0", "TrailingPE": "33.89", "ForwardPE": "56.5", "PriceToSalesRatioTTM": "12.86", "PriceToBookRatio": "6.18", "EVToRevenue": "11.64", "EVToEBITDA": "82.26", "Beta": "0.04", "52WeekHigh": "678.21", "52WeekLow": "457.42", "50DayMovingAverage": "575.32", "200DayMovingAverage": "594.45", "SharesOutstanding": "61200000", "SharesFloat": "60937000", "PercentInsiders": "0.001", "PercentInstitutions": "55.509", "DividendDate": "None", "ExDividendDate": "None"}